Evidence map›Paper›PMID 40820259›Full record

ArticleProteins2026

CASP16 Protein Monomer Structure Prediction Assessment.

Rongqing Yuan, Jing Zhang, Andriy Kryshtafovych, R Dustin Schaeffer, Jian Zhou, Qian Cong, Nick V Grishin

Abstract read
In one paragraph

Article in Proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Rongqing YuanEugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0001-5917-4505
Jing ZhangEugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0003-4190-3065
Andriy KryshtafovychGenome Center, University of California, Davis, California, USA.ORCID https://orcid.org/0000-0001-5066-7178
R Dustin SchaefferDepartment of Biophysics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jian ZhouLyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Qian CongEugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0002-8909-0414
Nick V GrishinDepartment of Biophysics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Funding

Prospective analysis to determine model accuracy performance and boundaries in the post-AlphaFold2 environmentR01GM100482 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FIDELIS, KRZYSZTOF A · 2012 to 2025
$11.1M
ECOD: Large scale classification of predicted and experimental protein structuresR01GM147367 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI Richard Dustin Schaeffer · 2023 to 2026
$1.4M
Functions of Rapidly-Evolving Proteins and Their Roles in PathogenicityK99AI180984 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, JING · 2024 to 2025
$210k
National Science Foundation Division of Biological Infrastructure 2224128NIAID NIH HHS K99 AI180984NIAID NIH HHS K99AI180984-01A1NIGMS NIH HHS GM100482NIGMS NIH HHS GM147367NIGMS NIH HHS R01 GM100482NIGMS NIH HHS R01 GM147367NVG Welch Foundation I-1505NVG Welch Foundation I-2095-20220331The Cancer Prevention and Research Institute of Texas RR190017The Endowed Scholars Program in UTSW
6 · The paper itself

Abstract

The assessment of monomer targets in the Critical Assessment of Structure Prediction Round 16 (CASP16) underscores that the problem of single-domain protein fold prediction is nearly solved-no target folds were incorrectly predicted across all Evaluation Units. However, challenges remain in accurately modeling truncated sequences, irregular secondary structures, and interaction-induced conformational changes. The release of AlphaFold3 (AF3) during CASP16, and its effective integration by many groups, demonstrated its superiority over AlphaFold2 (AF2), particularly in confidence estimation and model selection. Additional improvements in multiple sequence alignments (MSAs) and fragment-based prediction, that is, selecting the optimal fragment of the full sequence for modeling, also contributed to enhanced prediction accuracy. The top three groups-all from the Yang lab-consistently outperformed others across CASP16 monomer targets, reflecting their robust modeling pipelines and successful adoption of AF3. CASP16 also introduced three new challenges: Phase 0, in which stoichiometry was withheld; Phase 2, which supplied ~8000 MassiveFold models per target to test model selection strategies; and Model 6, which limited predictors to using MSAs provided by the organizers. While we evaluated group performance in these additional challenges, the insights gained were limited due to low participation and caveats in the design of experiments. We suggest improvements for the organization of these challenges and encourage broader engagement from the prediction community. The progress in monomer modeling from CASP15 to CASP16 was subtle, but more groups in CASP16 were able to outperform ColabFold, reflecting the community's improved ability in optimizing AF2 and the growing adoption of AF3. We anticipate that the recent release of the AF3 source code will stimulate future progress through user-driven optimization and innovations in model architecture. Finally, model ranking remains a persistent weakness across most groups, highlighting a critical area for future development.

Indexed as

Computational BiologyProteinsSoftwareAlgorithmsDatabases, ProteinModels, MolecularProtein ConformationProtein FoldingProtein Structure, SecondarySequence AlignmentProteinsAlphaFold2AlphaFold3CASP16monomerprotein structure predictionquality estimationstoichiometrystructure sampling

Identifiers

PMID40820259
PMCPMC12750037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.